FDA warns of fetal risk with transplant drugs
WASHINGTON (Reuters) - U.S. health officials issued an alert on Friday about the risks of miscarriages and birth defects from Novartis AGand Roche Holding AG transplant drugs.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=Bf4jQa" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=Bf4jQa)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=W9IxNH" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=W9IxNH) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=FcaElh" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=FcaElh) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=WE9DZh" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=WE9DZh)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/291711724" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/291711724/idUSWAT00949620080516